Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy

Molecular Cancer Therapeutics

Volumn 14, Issue 2, 2015, Pages 523-532

  Singha, Netai C ^a   Nekoroski, Tara ^a   Zhao, Chunmei ^a   Symons, Rebecca ^a   Jiang, Ping ^a   Frost, Gregory I ^b   Huang, Zhongdong ^a   Shepard, H Michael ^a  

^a Halozyme Therapeutics Inc   (United States)

^b INTREXON CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; HYALURONIC ACID; MONOCLONAL ANTIBODY; PEGPH 20; RECOMBINANT HYALURONIDASE; TRASTUZUMAB; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG EFFICACY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; ANIMAL; CELL COMMUNICATION; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; EXTRACELLULAR MATRIX; FEMALE; METABOLISM; NATURAL KILLER CELL; NEOPLASMS; NUDE MOUSE; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL COMMUNICATION; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR MATRIX; FEMALE; HUMANS; HYALURONIC ACID; KILLER CELLS, NATURAL; MICE, NUDE; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923360149     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0580     Document Type: Article

References (50)

1. Auvinen P, Tammi R, Kosma VM, Sironen R, Soini Y, Mannermaa A, et al. Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer. Int J Cancer 2013;132:531-9.
2. Boregowda RK, Appaiah HN, Siddaiah M, Kumarswamy SB, Sunila S, Thimmaiah KN, et al. Expression of hyaluronan in human tumor progression. J Carcinog 2006;5:2.
3. Kultti A, Li X, Jiang P, Thompson CB, Frost GI, Shepard HM. Therapeutic targeting of hyaluronan in the tumor stroma. Cancers 2012;4:873-903.
4. Sironen RK, Tammi M, Tammi R, Auvinen PK, Anttila M, Kosma VM. Hyaluronan in human malignancies. Exp Cell Res 2011;317:383-91.
5. Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK. Proteoglycans in health and disease: novel roles for proteoglycans inmalignancy and their pharmacological targeting. FEBS J 2010;277:3904-23.
6. Day AJ, Prestwich GD. Hyaluronan-binding proteins: tying up the giants. J Biol Chem 2002;277:4585-8.
7. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013;31:2205-18.
8. Thompson CB, Shepard HM, O'Connor PM, Kadhim S, Jiang P, Osgood RJ, et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther 2010;9:3052-64.
9. Jiang P, Li X, Thompson CB, Huang Z, Araiza F, Osgood R, et al. Effective targeting of the tumor microenvironment for cancer therapy. Anticancer Res 2012;32:1203-12.
10. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013;62:112-20.
11. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21:418-29.
12. Gately CL, Muul LM, Greenwood MA, Papazoglou S, Dick SJ, Kornblith PL, et al. In vitro studies on the cell-mediatedimmune response to human brain tumors. II. Leukocyte-induced coats of glycosaminoglycan increase the resistance of glioma cells to cellular immune attack. J Immunol 1984;133:3387-95.
13. McBride WH, Bard JB. Hyaluronidase-sensitive halos around adherent cells. Their role in blocking lymphocyte-mediated cytolysis. J Exp Med 1979;149:507-15.
14. Dick SJ, Macchi B, Papazoglou S, Oldfield EH, Kornblith PL, Smith BH, et al. Lymphoid cell-glioma cell interaction enhances cell coat production by human gliomas: novel suppressor mechanism. Science 1983;220:739-42.
15. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006;1:119-50.
16. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57.
17. Shepard HM, Brdlik CM, Schreiber H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 2008;118:3574-81.
18. Pillay V, Gan HK, Scott AM. Antibodies in oncology. Nat Biotechnol 2011;28:518-29.
19. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-85.
20. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74.
21. Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res 2009;15:7471-8.
22. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6:443-6.
23. Nahta R, Esteva FJ. Herceptin: mechanism of action and resistance. Cancer Lett 2006;232:123-38.
24. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010;28:1254-61.
25. Shiao SL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev 2011;25:2559-72.
26. Neesse A, Krug S, Gress TM, Tuveson DA, Michl P. Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther 2013;7:33-43.
27. Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, et al. Fcg R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 2011;22:1302-7.
28. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8.
29. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
30. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47:115-23.
31. +natural killer cells. Hum Immunol 2001;62:1092-8.
32. Festing MF. Design and statistical methods in studies using animal models of development. ILAR J 2006;47:5-14.
33. St. Croix B, Man S, Kerbel RS. Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Lett 1998;131:35-44.
34. Váradi T, Mersich T, Auvinen P, Tammi R, Tammi M, Salamon F, et al. Binding of trastuzumab to ErbB2 is inhibited by a high pericellular density of hyaluronan. J Histochem Cytochem 2012;60:567-75.
35. Pályi-Krekk Z, Barok M, Isola J, Tammi M, Szöllosi J, Nagy P. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer 2007;43:2423-33.
36. Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 1997;242:27-33.
37. Ween MP, Oehler MK, Ricciardelli C. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int J Mol Sci 2011;12:1009-29.
38. Ricciardelli C, Sakko AJ, Ween MP, Russell DL, Horsfall DJ. The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev 2009;28:233-45.
39. Kovar JL, Johnson MA, Volcheck WM, Chen J, Simpson MA. Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse model. Am J Pathol 2006;169:1415-26.
40. Lokeshwar VB, Mirza S, Jordan A. Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv Cancer Res 2014;123:35-65.
41. Sáez R, Molina MA, Ramsey EE, Rojo F, Keenan EJ, Albanell J, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006;12:424-31.
42. Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007;99:628-38.
43. Sugarman BJ, Lewis GD, Eessalu TE, Aggarwal BB, Shepard HM. Effects of growth factors on the antiproliferative activity of tumor necrosis factors. Cancer Res 1987;47:780-6.
44. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006;66:5527-36.
45. Hudziak RM, Lewis GD, Shalaby MR, Eessalu TE, Aggarwal BB, Ullrich A, et al. Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. Proc Natl Acad Sci U S A 1988;85:5102-6.
46. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-96.
47. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-77.
48. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108:804-11.
49. + regulatory T cells. J Leukoc Biol 2009;86:567-72.
50. Sund M, Kalluri R. Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev 2009;28:177-83.